Answers are grounded in this paper and cite their sources.
Collateral artery growth is accompanied by kininogen expression, the substrate for kinins which signal via bradykinin receptors 1 and 2 (B1R, B2R). Here, the role of BR signaling in peripheral and cerebral arteriogenesis was analysed in the femoral artery occlusion (FAO) model in mice (C57Bl/6, B1R−/−, B2R −/−), and in rats (sprague dawley), which were subjected to 3-vessel occlusion (3-VO). Arteriogenesis was modulated therapeutically by the application of B1R and B2R agonists/antagonists and the mechanism of B1R signaling in arteriogenesis was elucidated by performing crosswise bone marrow transplantation (B1R −/−, WT). 7 days post FAO BR −/− mice show significant reduction of collateral perfusion, with B1R −/− mice exhibiting the strongest phenotype (−50%). Arteriogenesis can be inhibited by B1R and B2R antagonists and stimulated by B1R agonists. Injection of WT bone marrow into B1R −/− rescued the impaired arteriogenesis of B1R deficient mice and vice versa collateral perfusion was reduced to levels of B1R −/− mice. Histological immunostainings validated inhibition/induction of leucocyte migration in response to selective B1R antagonist/agonist treatment. In conclusion, BRs are relevant for collateral artery growth, which can be therapeutically modulated by BR antagonists/agonists, and in particular depend on B1R expression on bone-marrow derived cells.
No takes yet. Share an insight, caveat, or question.
Hillmeister et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: